Related references
Note: Only part of the references are listed.Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A. Cervantes et al.
ANNALS OF ONCOLOGY (2023)
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial
Marc Ychou et al.
BRITISH JOURNAL OF CANCER (2022)
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Phis Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
Daniele Rossini et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis
Brett L. Ecker et al.
LANCET ONCOLOGY (2022)
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis
Filippo Pietrantonio et al.
ONCOLOGIST (2021)
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
Chiara Cremolini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review
Karen Bolhuis et al.
EUROPEAN JOURNAL OF CANCER (2020)
Outcomes of Resectability Assessment of the Dutch Colorectal Cancer Group Liver Metastases Expert Panel
Joost Huiskens et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2019)
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3
D. P. Modest et al.
EUROPEAN JOURNAL OF CANCER (2018)
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
Alfredo Carrato et al.
EUROPEAN JOURNAL OF CANCER (2017)
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
Julian Walter Holch et al.
EUROPEAN JOURNAL OF CANCER (2017)
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma
Fernando Rivera et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2017)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
Alan P. Venook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D. Arnold et al.
ANNALS OF ONCOLOGY (2017)
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG)
Joost Huiskens et al.
BMC CANCER (2015)
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
Filippo Pietrantonio et al.
EUROPEAN JOURNAL OF CANCER (2015)
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)
Volker Heinemann et al.
EUROPEAN JOURNAL OF CANCER (2015)
Progression-Free Survival: Helpful Biomarker or Clinically Meaningless End Point?
Alan P. Venook et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
T. Gruenberger et al.
ANNALS OF ONCOLOGY (2015)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
Bernard Nordlinger et al.
LANCET ONCOLOGY (2013)
Impact of Expanding Criteria for Resectability of Colorectal Metastases on Short- and Long-Term Outcomes After Hepatic Resection
Robbert J. de Haas et al.
ANNALS OF SURGERY (2011)
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
Gunnar Folprecht et al.
LANCET ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey
D Dindo et al.
ANNALS OF SURGERY (2004)
Share Paper
